The Group currently expects H1 FY23 Revenue to exceed $47m, and with seven (7) months still left to run in FY23, based on new sales activity underway, we appear well on track to deliver another record set of stellar full year results.
I like the sound of this.
- Forums
- ASX - By Stock
- HCL
- Ann: XTEK 2022 AGM Group CEO Presentation
Ann: XTEK 2022 AGM Group CEO Presentation, page-4
Featured News
Add HCL (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.42M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 155104 | 16.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.0¢ | 56050 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 155104 | 0.160 |
4 | 42741 | 0.155 |
3 | 138445 | 0.150 |
1 | 10500 | 0.145 |
2 | 103590 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.170 | 56050 | 2 |
0.175 | 70500 | 2 |
0.180 | 146367 | 4 |
0.185 | 8576 | 1 |
0.190 | 25000 | 1 |
Last trade - 16.12pm 15/11/2024 (20 minute delay) ? |
Featured News
HCL (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online